|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.02 USD | -0.78% |
|
+24.59% | +156.03% |
| Apr. 11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
| Apr. 03 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
On march 25, 2024, Q32 Bio Inc. closed the transaction.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 44.85 USD | +0.34% | -8.34% | 90.92B | ||
| 28.02 USD | -0.78% | +24.59% | 334M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +156.03% | 334M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
Q32 BIO INC. 
